Abstracts Archive - Page 100 of 2425 - ACR Meeting Abstracts

Abstract Number: 0957 • ACR Convergence 2024
Increased Collagen Deposition and Altered Immune Cell Profiles Are Present in Early and Late Stage Systemic Sclerosis with Gastrointestinal Involvement
Laura Much¹, Elena Pachera², Andrea Laimbacher¹, Henriette Didriksen³, Lars Aabakken⁴, Knut Ea Lundin⁴, Lumeng Li¹, Astrid Hofman¹, Pietro Bearzi⁵, Sophie Wagner⁶, Michael Scharl⁷, Øyvind Molberg⁸, Håvard Fretheim⁹, Oliver Distler¹⁰ and Anna-Maria Hoffmann-Vold⁹, ¹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ²University Hospital Zurich, Zurich, Switzerland, ³Oslo University Hospital, Moss, Norway, ⁴Department of Transplantation Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway, ⁵Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Schlieren, Switzerland, ⁶University of Zurich, Schlieren, Switzerland, ⁷Department of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁸Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, ⁹Oslo University Hospital, Oslo, Norway, ¹⁰Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland
Background/Purpose: Gastrointestinal tract (GIT) involvement is highly prevalent among patients with systemic sclerosis (SSc) and is associated with high morbidity and mortality. However, treatment options…
Abstract Number: 0926 • ACR Convergence 2024
Macrophages and Nociceptor Neurons Form a Sentinel Unit Around Fenestrated Capillaries to Defend the Synovium from Systemic Challenges
Tetsuo Hasegawa and Menna Clatworthy, University of Cambridge, Cambridge, United Kingdom
Background/Purpose: A wide variety of systemic pathologies, including infectious and autoimmune diseases, are accompanied by joint pain or inflammation, often mediated by circulating immune complexes…
Abstract Number: 0762 • ACR Convergence 2024
Different Giant Cell Arteritis Phenotypes May Present Distinct Types of Ischemic Complications
Helena M Amar Muñoz¹, Juan Molina-Collada¹, Isabel Castrejon², irene monjo³, Elisa Fernández-Fernández:⁴, José María Álvaro-Gracia⁵ and Eugenio De Miguel⁶, ¹Hospital General Universitario Gregorio Marañón, MADRID, Spain, ²Hospital General Universitario Gregorio Marañon, Madrid, Spain, ³University Hospital La Paz, Madrid, Spain, ⁴La Paz University Hospital, Alcalá de Henares, Madrid, Spain, ⁵Hospital Gregorio Marañón, Madrid, Spain, ⁶Hospital Universitario La Paz, Madrid, Spain
Background/Purpose: To determine if the subtype of vascular ultrasound (US) presentation is associated with different types of ischemic complications (IC) in giant cell arteritis (GCA).Methods: Retrospective…
Abstract Number: 0518 • ACR Convergence 2024
Sustained Patient Meaningful Outcomes of Pain and Fatigue Relief and Improved Physical Functioning with Filgotinib in Rheumatoid Arthritis: A Post Hoc Analysis
Rieke Alten¹, Bruno Fautrel², Philip G Conaghan³, Dick de Vries⁴, Margaux Faes⁵, Mercedes Piovesan⁶, Katrien Van Beneden⁷, Chris Watson⁸, Angelique E.A.M. Weel-Koenders⁹, Eugen Feist¹⁰ and Kurt de Vlam¹¹, ¹Department of Internal Medicine and Rheumatology, Schlosspark Klinik, University Medicine Berlin, Berlin, Germany, ²INSERM, UMRS 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Sorbonne University – Assistance Publique-Hôpitaux de Paris, Département de Rhumatologie, Hôpital Pitié-Salpêtrière, Paris, Ile-de-France, France, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁴Clinical Development, Galapagos BV, Leiden, Netherlands, ⁵Biostatistics, Galapagos NV, Mechelen, Belgium, ⁶Medical Affairs, Galapagos Biopharma Spain SLU, Madrid, Spain, ⁷Medical Affairs, Galapagos NV, Mechelen, Belgium, ⁸Medical Affairs, Galapagos Biotech Ltd, Cambridge, United Kingdom, ⁹Erasmus School of Health Policy and Management, Erasmus University Rotterdam, and Department of Rheumatology and Clinical Immunology, Maasstad Hospital, Rotterdam, Netherlands, ¹⁰Department of Rheumatology, Helios Clinic Vogelsang-Gommern, cooperation partner of the Otto von Guericke University Magdeburg, Gommern, Germany, ¹¹Department of Rheumatology, UZ Leuven, and Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, KU Leuven, Leuven, Belgium
Background/Purpose: Quality of life for patients with RA can be severely impacted by pain, fatigue and impaired physical functioning.1 Filgotinib (FIL) has demonstrated early onset…
Abstract Number: 1495 • ACR Convergence 2024
Real-World Reduction in Disease Flares and Oral Corticosteroid Use with Anifrolumab Therapy in Systemic Lupus Erythematosus: A Claims-Based Study
Mawuena Binka¹, Rana Muhammad Qasim Khan², Joseph Tkacz³, Donna McMorrow³, Laurence Gozalo³ and Gail Kerr⁴, ¹BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, ²BioPharmaceuticals Medical, AstraZeneca, Wilmington, ³Inovalon, Bowie, MD, ⁴Veterans Affairs Medical Center, Georgetown and Howard University Hospitals, Washington, DC
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex, chronic autoimmune disease characterized by frequent episodes of disease activity (flares) of varying severity.1 SLE flares are…
Abstract Number: 0966 • ACR Convergence 2024
CDDO-Me Attenuates Pro-fibrotic Activation in Macrophages and Fibroblasts in Systemic Sclerosis
Heetaek Yang¹, Chanhyuk Park², Chen-Yu Wang³, Emily Morris⁴, Karen Liby⁵, Michael Whitfield⁶ and Patricia Pioli², ¹Dartmouth College, West Lebanon, NH, ²Geisel School of Medicine at Dartmouth, Lebanon, NH, ³Dartmouth College, Lebanon, NH, ⁴Dartmouth College, Enfield, NH, ⁵Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, IN, ⁶Geisel School of Medicine at Dartmouth, Hanover, NH
Background/Purpose: Systemic Sclerosis (SSc) is characterized by dysfunctional immune activation, oxidative stress, and fibrosis. In prior work, we have shown that SSc macrophages (MØs) have…
Abstract Number: 0888 • ACR Convergence 2024
Genetically Determined Peptidylglycine Alpha-amidating Monooxygenase (PAM) Mediated Amidation Regulates Tissue Damage by Rheumatoid Arthritis Synovial Fibroblasts
Kevin Sheridan¹, Emma Doris¹, Maria Pimenta¹, Jemma Falkov¹, Matthew Fisher², Munitta Muthana², Denis Shields¹, Richard Mains³, Betty Eipper³, Christopher Buckley⁴ and Anthony Wilson⁵, ¹University College Dublin, Dublin, Ireland, ²University of Sheffield, Sheffield, United Kingdom, ³University of Connecticut, Connecticut, ⁴University of Oxford, Oxford, United Kingdom, ⁵UCD, Dublin, Dublin, Ireland
Background/Purpose: The SNP rs26232 is associated with both risk and severity of rheumatoid arthritis (RA), with the C allele associated with the susceptibility to RA,…
Abstract Number: 0913 • ACR Convergence 2024
The Association Between PTPN2 and Leukopenia in New Users of Azathioprine
Puran Nepal¹, Laura L. Daniel², Jacy Zanussi², Alyson L. Dickson³, Wei-Qi Wei³, Adriana M. Hung⁴, Nancy J. Cox³, Vivian K. Kawai³, Jonathan D. Mosley³, C. Michael Stein³, QiPing Feng³, Ge Liu³, Ran Tao³ and Cecilia P. Chung², ¹Vanderbilt University Medical Center, Vanderbilt, TN, ²University of Miami, Miami, FL, ³Vanderbilt University Medical Center, Nashville, TN, ⁴Veterans Administration Tennessee Valley Healthcare System, Nashville, TN
Background/Purpose: Leukopenia is a common dose-dependent side effect of azathioprine and often results in discontinuation of the drug. Variants in TPMT and NUDT15 have been…
Abstract Number: 0772 • ACR Convergence 2024
Global Recruiting Patterns Are Associated with Placebo Response Rates in Clinical Trials of Psoriatic Arthritis
Andreas Kerschbaumer¹, Marlene Steiner², Suzanne D. Khalili¹, Daniel Aletaha³ and Josef Smolen⁴, ¹Medical University of Vienna, Vienna, Wien, Austria, ²Medical University Vienna, Vienna, Wien, Austria, ³Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Wien, Austria, ⁴Medical University of Vienna, Vienna, Austria
Background/Purpose: Therapeutic advances of the recent past have led to significant changes in clinical practice when treating patients with psoriatic arthritis (PsA). Since the advent…
Abstract Number: 0528 • ACR Convergence 2024
Consequences of Switching Originator Biological Therapies to Its Biosimilars in Patients with Immune-mediated Diseases in a Mexican Cohort
Sandra Carrillo¹, Daniel Xibille², Martha Mariana Castañeda-Martínez³, Alfredo Reyes⁴, Brian garcia-Arellano⁵, Edgar Vega Chávez⁶, Carlos vidal Montiel Castañeda⁵, Gabriel Carmona Lara⁶ and Gilberto De Hoyos⁵, ¹Hospital Angeles Lindavista, Mexico City, Distrito Federal, Mexico, ²Servicios de Salud de Morelos, Cuernavaca, Morelos, Mexico, ³ISSSTE, Monterrey, Mexico, ⁴ISSSTE, Ciudad de México, Mexico, ⁵ISSSTE, Ciudad de México, Distrito Federal, Mexico, ⁶ISSSTE, Ciudad de mexico, Distrito Federal, Mexico
Background/Purpose: Biological agents such as the TNF-α inhibitors have had a positive impact on the treatment of many chronic autoimmune diseases (AIDs), such as Rheumatoid…
Abstract Number: 0025 • ACR Convergence 2024
Vagus Nerve Stimulation: A Promising Approach to Alleviate Pain and Systemic Inflammation in Slow and Rapid Models of Osteoarthritis
Shivmurat Yadav¹, Timothy Griffin², Matlock Jeffries², Stavros Stavrakis³ and Mary Beth Humphrey⁴, ¹University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³University of Oklahoma, College of Mediicine, Oklahoma City, OK, ⁴University of Oklahoma College of Medicine, Oklahoma City, OK
Background/Purpose: Osteoarthritis (OA) causes joint pain, stiffness, swelling, and functional impairment. Pain signals reach the brain, influencing inflammatory and immune responses through the parasympathetic efferent…
Abstract Number: 0979 • ACR Convergence 2024
The Joint Project: A Community-Based, Barangay Health Worker-Led Screening Program for Childhood Musculoskeletal Disorders in a Barangay in San Pedro, Laguna, Philippines
Ma Theresa Collante¹ and Leilani Mercado-Asis², ¹University of Santo Tomas, San Pedro, Laguna, Philippines, ²University of Santo Tomas, Man, National Capital Region, Philippines
Background/Purpose: Musculoskeletal diseases (MSD) are relevant across the life-course – from childhood to older age. In children, the most common MSD are fractures, scoliosis, arthritis…
Abstract Number: 0923 • ACR Convergence 2024
Immunization of Arthritis Prone Mice with Malondialdehyde-Acetaldehyde Modified Vimentin Induces Post-Translational Protein Modifications and Extracellular Matrix Deposition in Heart Tissues
Kimberley Sinanan¹, Wenxian Zhou², Michael Duryee¹, Nozima Aripova¹, Jill Poole¹, Carlos Hunter¹, Amy Nelson¹, Tate Johnson¹, Daniel Anderson³, Ted Mikuls¹ and Geoffrey Thiele¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Medical Center, Bellevue, NE, ³University of Nebraska Medical Center, Durham, NC
Background/Purpose: Recent studies have highlighted the importance of malondialdehyde-acetaldehyde (MAA)-modified proteins and resulting immune responses in the pathogenesis of rheumatoid arthritis (RA). MAA adducts have…
Abstract Number: 0947 • ACR Convergence 2024
REX-7117 Is a Highly Potent and Selective Oral STAT3 Inhibitor That Demonstrated Potential Efficacy and Safety Differentiation versus JAK/TYK2 Targeting in Preclinical Models of Inflammatory Arthritis
Alexandra Gardino¹, Neil Bifulco¹, Jeremy Hunt², Rishi Vaswani¹, Donglim Park², Patrick Metz², Ksenya Cohen-Katsenelson², Jeong-Ho Kim², Xia Tian², Aryan Alavi², Ajay Nirula², Daniel Treiber², Brian Hodous¹, Seong Kim³ and Paul Smith², ¹Recludix Pharma, Cambridge, MA, ²Recludix Pharma, San Diego, CA, ³Department of Microbiology and Immunology, LSU Health Shreveport, Shreveport, LA
Background/Purpose: Inhibition of JAK family signaling has translated into clinically meaningful efficacy in rheumatoid arthritis, psoriatic arthritis and other inflammatory diseases. However, small molecule JAK/TYK2…
Abstract Number: 0785 • ACR Convergence 2024
Exploring the Link Between Atgl-Dependent Lipolysis and Dermal Fibrosis in Systemic Sclerosis
Elizabeth Caves¹, Agrani Dixit¹, Anna Jussila², Vivian Lei³, Hailey Edelman⁴, Muhammad Hamdan⁵, Ian Odell⁵, Monique Hinchcliff⁶, Radhika Atit⁷ and Valerie Horsley¹, ¹Yale School of Medicine, New Haven, CT, ²Stanford Medicine, Stanford, CA, ³University of North Carolina School of Medicine, Chapel Hill, ⁴Vanderbilt School of Engineering, New Haven, ⁵Yale School of Medicine, New Haven, ⁶Yale School of Medicine, Westport, CT, ⁷Case Western Reserve University College of Arts and Sciences, Cleveland
Background/Purpose: Resident lipid-filled dermal adipocytes are depleted in both systemic sclerosis (SSc) and scleroderma mouse models, but mechanisms are poorly understood. We undertook studies in mouse…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].